Ginkgo touts gene therapy one-stop shop capabilities following acquisition

Ginkgo acquires StrideBio's adeno-associated virus (AAV) capsid discovery and engineering platform assets and as well as gaining ownership of a preclinical asset.

Related Keywords

Narendra Maheshri , ,Sarepta Therapeutics ,Sensible Biotechnologies ,Markets Amp Regulations ,Hav ,Gene Therapies ,Adeno Associated Virus ,Ringko ,Stridebio ,Gene Therapy ,